Hepatobiliary scintigraphy and kinetic growth rate predict liver failure after ALPPS: a multi-institutional study.

Hepatectomy / adverse effects Humans Liver / diagnostic imaging Liver Failure / diagnostic imaging Liver Neoplasms / diagnostic imaging Portal Vein / diagnostic imaging Radionuclide Imaging Retrospective Studies

Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
10 2020
Historique:
received: 19 11 2019
revised: 14 01 2020
accepted: 19 01 2020
pubmed: 15 2 2020
medline: 26 10 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

Post hepatectomy liver failure (PHLF) after ALPPS has been related to the discrepancy between liver volume and function. Pre-operative hepatobiliary scintigraphy (HBS) can predict post-operative liver function and guide when it is safe to proceed with major hepatectomy. Aim of this study was to evaluate the role of HBS in predicting PHLF after ALPPS, defining a safe cut-off. A multicenter retrospective study was approved by the ALPPS Registry. All patients selected for ALPPS between 2012 and 2018, were evaluated. Every patient underwent HBS during ALPPS evaluation. PHLF was reported according to ISGLS definition, considering grade B or C as clinically significant. 98 patients were included. Thirteen patients experienced PHLF grade B or C (14%) following ALPPS-2. The HBS and the daily gain in volume (KGR Patients presenting a KGR

Sections du résumé

BACKGROUND
Post hepatectomy liver failure (PHLF) after ALPPS has been related to the discrepancy between liver volume and function. Pre-operative hepatobiliary scintigraphy (HBS) can predict post-operative liver function and guide when it is safe to proceed with major hepatectomy. Aim of this study was to evaluate the role of HBS in predicting PHLF after ALPPS, defining a safe cut-off.
METHODS
A multicenter retrospective study was approved by the ALPPS Registry. All patients selected for ALPPS between 2012 and 2018, were evaluated. Every patient underwent HBS during ALPPS evaluation. PHLF was reported according to ISGLS definition, considering grade B or C as clinically significant.
RESULTS
98 patients were included. Thirteen patients experienced PHLF grade B or C (14%) following ALPPS-2. The HBS and the daily gain in volume (KGR
CONCLUSION
Patients presenting a KGR

Identifiants

DOI: 10.1016/j.hpb.2020.01.010 PMID: 32057681
pubmed: 32057681
pii: S1365-182X(20)30029-0
doi: 10.1016/j.hpb.2020.01.010
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1420-1428

Informations de copyright

Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Federico Tomassini (F)

Department of Human Structure and Repair, Ghent University Faculty of Medicine, B-9000 Ghent, Belgium.

Yves D'Asseler (Y)

Department of Nuclear Medicine, Ghent University Hospital, C Heymanslaan 10, B-9000 Ghent, Belgium.

Michael Linecker (M)

Swiss HPB Center, University Hospital Zurich, Switzerland.

Mariano C Giglio (MC)

Department of Clinical Medicine and Surgery, Federico II University Naples, Via S. Pansini 5, I-80131 Naples, Italy.

Carlos Castro-Benitez (C)

University Paris Sud, Unité INSERM 935, Paul Brousse University Hospital, F-94804 Villejuif, France.

Stéphanie Truant (S)

Department of Digestive Surgery and Transplantation, Lille University Hospital, F-59037 Lille, France.

Rimma Axelsson (R)

Karolinska University Hospital, Imaging and Function, Medical Radiation Physics and Nuclear Medicine, Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Radiology, Stockholm, Sweden.

Pim B Olthof (PB)

Department of Surgery, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Surgery, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.

Roberto Montalti (R)

Department of Clinical Medicine and Surgery, Federico II University Naples, Via S. Pansini 5, I-80131 Naples, Italy; Department of Public Health, Federico II University Naples, Via S. Pansini 5, I-80131 Naples, Italy.

Matteo Serenari (M)

Department of Medical and Surgical Sciences, University of Bologna, Italy.

Thiery Chapelle (T)

Department of Hepatobiliary, Transplantation, and Endocrine Surgery, Antwerp University Hospital, Antwerp, Belgium.

Valerio Lucidi (V)

Department of Digestive Surgery, Unit of Hepato-Biliary Surgery and Transplantation, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Ernesto Sparrelid (E)

Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

René Adam (R)

University Paris Sud, Unité INSERM 935, Paul Brousse University Hospital, F-94804 Villejuif, France.

Thomas Van Gulik (T)

Department of Surgery, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.

François-René Pruvot (FR)

Department of Digestive Surgery and Transplantation, Lille University Hospital, F-59037 Lille, France.

Pierre-Alain Clavien (PA)

Swiss HPB Center, University Hospital Zurich, Switzerland.

Dario Bruzzese (D)

Department of Public Health, Federico II University Naples, Via S. Pansini 5, I-80131 Naples, Italy.

Karen Geboes (K)

Department of Gastroenterology-Digestive Oncology, Ghent University Hospital, C Heymanslaan 10, 9000 Ghent, Belgium.

Roberto I Troisi (RI)

Department of Human Structure and Repair, Ghent University Faculty of Medicine, B-9000 Ghent, Belgium; Department of Clinical Medicine and Surgery, Federico II University Naples, Via S. Pansini 5, I-80131 Naples, Italy. Electronic address: roberto.troisi@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie digestive › Hépatectomie › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Système digestif › Foie › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Insuffisance hépatique › Défaillance hépatique › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Système cardiovasculaire › Vaisseaux sanguins › Veines › Système porte › Veine porte › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Hepatobiliary scintigraphy and kinetic growth...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Hepatobiliary scintigraphy and kinetic growth...